Clinical trials: Ischemia, Brain
Acute Ischemic Stroke, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics…
- Trial name
- ASSENT (NCT02586233)
- Testing
- DS-1040b
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Daiichi Sankyo
Cerebral Ischemia, Cerebral Infarction
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with…
- Conditions
- Cerebral Ischemia, Cerebral Infarction, Stroke, Acute
- Trial name
- NCT04047563
- Testing
- Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
- Where
- 11 sites in India
- Volunteers
- 158 people
- Sponsor
- Pharmazz, Inc.
Acute Ischemic Stroke
Study Evaluating Toro 88 Super Bore Aspiration Catheter for Acute Ischemic Stroke
The goal of this pilot study is to evaluate the safety and efficacy of the Toro 88 Super Bore Aspiration Catheter in acute ischemic stroke patients.
- Trial name
- TORO EFFECT FR (NCT07089355)
- Testing
- Toro 88 Super Bore Aspiration Catheter
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Toro Neurovascular, Inc.
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Acute Ischemic Stroke
DS1040b/Aspirin Drug/Drug Interaction Study
This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well…
- Trial name
- NCT02071004
- Testing
- DS-1040b, Aspirin
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Chronic Ischemic Stroke
A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke
This study is for adults who have difficulty moving a few months after a stroke. In this study, ASP2246 will be given to people for the first time. This is known as a "first in human" study.
- Trial name
- NCT07318714
- Testing
- ASP2246, Brain surgery, Rehabilitation therapy
- Where
- 5 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group
Acute Ischemic Stroke
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
- Trial name
- ReMEDy1 (NCT03290560)
- Testing
- Recombinant human tissue kallikrein
- Where
- 12 sites in Australia
- Volunteers
- 92 people
- Sponsor
- DiaMedica Therapeutics Inc
Tetraplegia/Tetraparesis, Quadriplegia
UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- UAE-PRIME (NCT06992596)
- Testing
- N1 Implant, R1 Robot
- Where
- United Arab Emirates
- Volunteers
- 10 people
- Sponsor
- Neuralink Corp
Stroke, Meningioma
Robot-Assisted Neurovascular Intervention
Patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.
- Conditions
- Stroke, Meningioma, Neurovascular Disorder
- Trial name
- NCT06752096
- Testing
- cerebral angiography, arterial embolization, thrombectomy, Cerebral angiogram using robotic device, Meningioma embolization using robotic device.
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Navigantis Inc.
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.
Ischemic Stroke
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
- Trial name
- NCT01958957
- Testing
- Ginkgolides Meglumine Injection
- Where
- 86 sites in China
- Volunteers
- 6,300 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Brain Ischemia
Xarelto [SPAF] Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.
- Trial name
- NCT01582737
- Testing
- Rivaroxaban(Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 11,310 people
- Sponsor
- Bayer
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Acute Ischemic Stroke
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset…
- Trial name
- SWIFT PRIME (NCT01657461)
- Testing
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Cerebrovascular Accident
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
- Trial name
- NCT00418275
- Testing
- Recombinant Human Plasminogen Activator (HTUPA)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Global Biotech
Stroke
REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS (NCT00663416)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 26 sites in Canada, India
- Volunteers
- 134 people
- Sponsor
- Stem Cell Therapeutics Corp.
Cerebral Stroke, Cerebrovascular Accident, Acute
Dapsone for Acute Ischemia Stroke Study
The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.
- Conditions
- Cerebral Stroke, Cerebrovascular Accident, Acute, Cerebrovascular Stroke, Stroke, Acute
- Trial name
- DAISY (NCT01144650)
- Testing
- Dapsone
- Where
- Mexico
- Volunteers
- 300 people
- Sponsor
- Cidat, S.A. de C.V.